Table 1.
Baseline characteristics
| Category | Subcategory | ICC (n = 174) | ||
|---|---|---|---|---|
| Age | n | 174 (100) | ||
| Median | 64 | |||
| IQR | 57–72 | |||
| Range | 29–88 | |||
| Sex | n | 174 (100) | ||
| Female | 73 (42) | |||
| Male | 97 (55.7) | |||
| Unknown | 4 (2.3) | |||
| Time since diagnosis (months) | n | 172 (98.9) | ||
| Median | 6.1 | |||
| IQR | 2.2–14.5 | |||
| ECOG status | n | 174 (100) | ||
| 0-Fully Active | 97 (55.7) | |||
| 1-Restricted | 61 (35.1) | |||
| 2 or higher | 12 (6.9) | |||
| Missing | 4 (2.3) | |||
| Extrahepatic disease prior to treatment | n | 174 (100) | ||
| No | 124 (71.3) | |||
| Yes | 50 (28.7) | |||
| Ascites | n | 174 (100) | ||
| No | 161 (92.5) | |||
| Yes | 13 (7.5) | |||
| Cirrhosis | n | 174 (100) | ||
| No | 153 (87.9) | |||
| Yes | 21 (12.1) | |||
| Location of liver tumours | n | 174 (100) | ||
| Bilobar | 86 (49.4) | |||
| Left only | 27 (15.5%) | |||
| Right only | 61 (35.1%) | |||
| Number of liver tumours | n | 174 (100) | ||
| 1 | 80 (46) | |||
| 2–5 | 35 (29.2) | |||
| 6–9 | 11 (6.3) | |||
| 10 or more | 12 (6.9) | |||
| Uncountable | 36 (20.7) | |||
| Methodology for determining the dose | n | 174 (100) | ||
| BSA or modified BSA | 87 (50) | |||
| Partition model | 87 (50) | |||
| Albumin (g/dL) | n | 141 (81) | ||
| Median (IQR) | 3.8 (3.4–4.2) | |||
| Bilirubin (µmol/L) | n | 172 (98.9) | ||
| Median (IQR) | 10 (7.2–14) | |||
| ALBI score | n | 140 (80.5) | ||
| Grade 1 | 72 (41.4) | |||
| Grade 2 | 67 (38.5) | |||
| Grade 3 | 1 (0.6) | |||
| INR | n | 134 (77) | ||
| Median (IQR) | 1.1 (1.0, 1.1) | |||
| ≤ 1 | 51 (29.3%) | |||
| > 1 | 83 (47.7) | |||
| Whole liver | Left lobe | Right lobe | ||
| Percentage of tumour invasion in the liver | n | 123 | 43 | 45 |
| < 10% | 46 (26.4) | 16 (9.2) | 22 (12.6) | |
| 10–20% | 37 (21.3) | 15 (8.6) | 10 (5.7) | |
| > 20% | 40 (23) | 12 (6.9) | 13 (7.5) | |
| Tumour burden | n | 170 (97.7) | ||
| < 10% | 60 (35.3) | |||
| 10–20% | 58 (34.1) | |||
| > 20% | 52 (31.6) | |||
| Prescribed activity (Giga-becquerel) | n | 91 | 83 | 83 |
| Median | 1.2 | 0.6 | 1.1 | |
| IQR | 0.9–1.6 | 0–1.0 | 0.7–1.4 | |
| Liver treatment target | n | 174 (100) | ||
| Whole liver (single catheter) | 13 (7.5) | |||
| Whole liver (split administration, single session) | 32 (18.4) | |||
| Whole liver (sequential lobar, two sessions) | 17 (9.8) | |||
| Right lobe | 62 (35.6) | |||
| Left lobe | 34 (19.5) | |||
| Segmental | 16 (9.2) | |||
| Delivered activity within 90% of prescribed (technical success) | n | 174 (100) | ||
| No | 4 (2.3) | |||
| Yes | 170 (97.7) | |||
N (%)
ALBI albumin-bilirubin, BSA body surface area, ECOG Eastern Cooperative Oncology Group, ICC intrahepatic cholangiocarcinoma, INR international normalised ratio, IQR interquartile range
Categories where percentages (%) do not add up to 100 are due to missing information